We Are Rats; If Pharma Could Be Brave … And Other Bullseye POVs You Won’t Hear at Other Events
MedCity News' new event for healthcare investors and corporate business development leads — Bullseye — hit the mark when it comes to provocative and thoughtful commentary. Here's what was said in panels throughout the day.
Why Hims & Hers Is Embroiled in Yet Another Controversy, This Time with the FTC
The FTC and the states of Utah and California sued Hims & Hers, alleging it improperly shared consumers’ health information and misled customers about billing, subscriptions and cancellations.
J&J Joins Immune Reset Race, Paying $785M to Partner on Sail Bio Cell Therapy
Johnson & Johnson also gains an exclusive option to acquire Sail Biosciences for $2.58 billion. The deal puts J&J in the mix of pharmaceutical companies developing next-generation cell therapies for applications in autoimmune diseases.
More Medications, Less Clarity: Strengthening Polypharmacy Support for CKD Patients
Interdisciplinary coordination between nephrologists, primary care providers, pharmacists, dieticians, and everyone who interacts with patients is essential to ensure patient education, improve adherence, and reduce medication errors.
The Code Gets You Paid — The Variant Gets You Treated
The between a code that satisfies a payer and the information a physician needs to treat a person, is what nearly every healthcare AI tool is racing past. As we push these systems toward precision medicine and genomics, that gap stops being an annoyance and becomes a patient safety issue.